Mar 5, 2025, 16:04
Yan Leyfman: Advancing CAR T-Cell Therapy – Faster and Effective for Lymphoma Patients
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn about a paper by Armin Ghobadi et al. published in eClinical Medicine:
“Advancing CAR T-Cell Therapy: Faster and Effective for Lymphoma Patients.
A phase I clinical trial evaluated the safety and feasibility of point-of-care CAR T-cell manufacturing, significantly reducing the time from apheresis to infusion (median: 13 days).
Key Findings:
- High Response Rates: 86% overall response, 76% complete response
- Survival Outcomes: 2-year progression-free survival: 63%, overall survival: 68%
- Comparable Safety Profile: CRS (65%), ICANS (32%), with a recommended phase 2 dose of 2 × 10⁶ MB-CART-19 cells/kg
Faster manufacturing could improve access for patients with rapidly progressing lymphoma – a critical step in personalized cancer treatment.”
Authors: Armin Ghobadi, Paolo Caimi, Jane Reese, Boro Dropulic, Marcos de Lima et al.
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 5, 2025, 15:54
Mar 5, 2025, 13:46
Mar 5, 2025, 13:01